Search results
Results from the WOW.Com Content Network
Horizon believed it could reach $1 billion peak sales in the US alone. In February 2021, the business announced it would acquire Viela Bio Inc for around $3 billion ($53 per share). [15] [16] In December 2022, the company announced it would be acquired by Amgen for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium). [17]
The U.S. Federal Trade Commission (FTC) has allowed Amgen to continue its $27.8 billion acquisition of Horizon Therapeutics, while preventing the drugmaker from using anticompetitive tactics to ...
The Federal Trade Commission will allow pharmaceutical giant Amgen to move ahead with its acquisition of Horizon Therapeutics, averting a trial set for September.
For premium support please call: 800-290-4726 more ways to reach us
In December, the company announced it would acquire Horizon Therapeutics for $27.8 billion ($116.50 in cash for each Horizon share, a 20% premium) expanding its rare disease treatments. [119] 2023: Amgen completed the acquisition of Horizon Therapeutics in October 2023. [120]
(Reuters) -The U.S. Federal Trade Commission (FTC) has suspended its challenge of Amgen's $27.8 billion purchase of Horizon Therapeutics, allowing the FTC to consider whether the agency should ...
Under the settlement terms with the FTC following its lawsuit to block the deal, Amgen is prevented from using anti-competitive tactics to extend the market dominance of Horizon's fast-growing ...
Tepezza, acquired from Horizon, generated $460 million in sales for the quarter (up 3%). These products underscore Amgen's capacity to seize growth opportunities, particularly in rare disease markets.